How I treat pregnancy-related venous thromboembolism
Key result
Pregnancy-related venous thromboembolism, complicating 1 to 2 of 1000 pregnancies, is treated with therapeutic low-molecular-weight heparin for a minimum of 3 months despite a lack of trial data.
Population
Pregnant women with venous thromboembolism (VTE)
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
LMWH remains standard for pregnancy-related VTE without RCT support; leaves open optimal regimen and duration, warranting dedicated trials.
Structured PICO
P
Population
Pregnant women with venous thromboembolism (VTE)
I
Intervention
Low-molecular-weight heparin (LMWH) in therapeutic doses during pregnancy, and LMWH or vitamin K antagonists postpartum
Management of pregnancy-related VTE relies on LMWH and multidisciplinary care, highlighting a critical need for dedicated clinical trials in this population.
Limitations
- A strong evidence base and clinical trial data for the optimal treatment of pregnancy-related VTE are missing.
- Management is not standardized between physicians, centers, and countries.
- It is unknown whether dosing should be based on weight or anti-Xa levels.
- Lack of strong evidence base
- Management based on extrapolation from nonpregnant population
- No clinical trial data for optimal treatment
Cite This Study
Saskia Middeldorp (2011) conducted a review in Pregnancy-related venous thromboembolism. Low-molecular-weight heparin (LMWH) was evaluated. Pregnancy-related venous thromboembolism, complicating 1 to 2 of 1000 pregnancies, is treated with therapeutic low-molecular-weight heparin for a minimum of 3 months despite a lack of trial data.